IGC Pharma (IGC) Stock Price, News & Analysis

Company Overview

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Key Stats

• Today's Range: $0.30 to $0.30
• 50-Day Range: $0.24 to $0.33
• 52-Week Range: $0.24 to $0.45
• Volume: 372,594 shs
• Average Volume: 1.14 million shs
• Market Capitalization: $30.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Moderate Buy

IGC Pharma Stock Analysis - MarketRank™

IGC Pharma scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IGC Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

IGC Pharma has a consensus price target of $5.50, representing about 1,745.6% upside from its current price of $0.30.

Amount of Analyst Coverage

IGC Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IGC Pharma are expected to grow in the coming year, from ($0.10) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGC Pharma is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGC Pharma is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGC Pharma has a P/B Ratio of 4.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.97% of the float of IGC Pharma has been sold short.

Short Interest Ratio / Days to Cover

IGC Pharma has a short interest ratio ("days to cover") of 0.74, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGC Pharma has recently increased by 41.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGC Pharma does not currently pay a dividend.

Dividend Growth

IGC Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

IGC Pharma has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IGC Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.87% of the stock of IGC Pharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:IGC
• Previous Symbol: NYSEMKT:IGC
• CIK: 1326205
• Web: igcpharma.com
• Phone: (301) 983-0998
• Fax: 240-465-0273
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IGC Pharma: $5.50
• High Price Target: $5.50
• Low Price Target: $5.50
• Potential Upside/Downside: +1,745.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: -543.82%
• Return on Equity: -99.21%
• Return on Assets: -74.18%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.39
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 24.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 4.97

Miscellaneous

• Outstanding Shares: 103,380,000
• Free Float: 78,923,000
• Market Cap: $30.81 million
• Optionable: N/A
• Beta: 0.48